α-Synuclein:帕金森病和相关疾病的有前途的生物标志物
Taku Hatano1, Ayami Okuzumi1, Gen Matsumoto2
1Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Journal of movement disorders
|April 8, 2024
概括
遗传帕金森病涉及SNCA基因突变和α-synuclein聚合. 种子放大试验为早期诊断和理解α-synucleinopathies提供了一个有希望的方法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物化学 生化学
背景情况:
- 编码alpha-synuclein (α-syn) 的SNCA基因中的突变是遗传帕金森病 (PD) 的核心.
- α-syn聚合物在PD中形成勒维体,在多重系统缩 (MSA) 中形成质细胞质内含体,这是α-synucleinopathies的关键特征.
- 在α-synucleinopathies中神经退行机制仍然不清楚,尽管α-syn聚合是标志性的.
研究的目的:
- 审查在体内监测α-syn聚合的潜力,作为诊断生物标志物.
- 探索种子放大试验 (SAA) 在检测致病性α-syn种子的早期诊断中的作用.
- 讨论α-syn光纤结构在疾病发病和诊断差异化中的影响.
主要方法:
- 关于α-synucleinopathies的文献综述,包括PD,MSA和勒维体痴呆症.
- 专注于种子放大试验 (SAA),如实时震动诱导的转换和蛋白质错误折叠周期放大.
- 提到结构分析技术,如传输电子显微镜和冷电子显微镜.
主要成果:
- SAA可以检测出微小数量的异常α-syn原纤维,这对于聚合至关重要.
- 跨α-syn核蛋白病变的α-syn纤维的结构差异表明不同的致病作用.
- SAA显示出区分α-synucleinopathy亚型和其他神经系统疾病的潜力.
结论:
- 体液中的致病性α-syn种子代表了重新定义α-synucleinopathies的诊断和分期的有希望的生物标志物.
- SAA对于准确的早期诊断,改善临床研究和神经退行性疾病中的生物标志物开发至关重要.
- 对血液中α-syn检测的进一步研究可能会提高诊断的可访问性.
关键词:
多重系统缩多重系统缩帕金森病是帕金森氏症的一种疾病.种子放大试验试验.α-Synuclein 是一种蛋白质.α-Synucleinopathy是指α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,是指α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy,即α-Synucleinopathy.相关概念视频
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264


